一周医药速览（12.1-12.5）

Group 1 - Lingke Pharmaceutical has submitted an IPO application to the Hong Kong Stock Exchange, with its core product LNK01001's commercialization fully entrusted to Xiansheng Pharmaceutical [1] - Lingke Pharmaceutical focuses on developing innovative drugs for oncology, immunology, and inflammatory diseases, with significant progress in its product pipeline [1] - The company has achieved major advancements with its core products LNK01001 and LNK01004, with the first candidate expected to enter the preclinical stage [1] Group 2 - Tongrentang Group plans to acquire a 60% stake in Tianjin Tongrentang, which will grant it control over the company [2] - The transaction is classified as a simplified case of operator concentration and is currently in the public notice phase [2] Group 3 - The National Healthcare Security Administration has launched a drug price registration and inquiry service to support the development of innovative drugs [3] - The service allows enterprises to voluntarily register drug prices, with a gradual expansion to other drugs, and operates under a principle of "one place acceptance, nationwide sharing, global openness" [3] Group 4 - Guizhou Bailing's actual controller Jiang Wei is under investigation by the China Securities Regulatory Commission for insider trading and information disclosure violations [5] - The investigation is focused solely on Jiang Wei as an individual and is not expected to impact the company's operations [6] Group 5 - Anke Biotechnology plans to invest HKD 112 million as a cornerstone investor in Baoji Pharmaceutical's IPO, aiming to deepen collaboration and enhance its product matrix in assisted reproduction [7] - Gaoguang Pharmaceutical has also submitted an IPO application to the Hong Kong Stock Exchange, focusing on therapies for autoimmune and inflammatory diseases [8] - The company has a differentiated asset portfolio with several candidates in clinical and preclinical stages, including TLL-018, a selective TYK2/JAK1 inhibitor [8]